{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-101414","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.243906+00:00","generated_at":"2026-05-17T21:59:50.257912+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Perspective Therapeutics updates corporate presentation; no material new data disclosed","bullets":["Updated corporate presentation filed August 1, 2025; no new clinical data or financial guidance disclosed.","Pipeline includes [212Pb]VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 targeting FAP-α.","Presentation notes sustained anti-tumor activity and tolerability for NET trial; no quantitative updates.","Pre-targeting platform and supply chain infrastructure highlighted as key differentiators."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-101414","json":"https://secwatch.observer/filing/0000950170-25-101414.json","markdown":"https://secwatch.observer/filing/0000950170-25-101414.md","text":"https://secwatch.observer/filing/0000950170-25-101414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017025101414/0000950170-25-101414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017025101414/catx-20250801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:59:50.257912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}